Co-Authors
This is a "connection" page, showing publications co-authored by Joseph Nkolola and Galit Alter.
Connection Strength
0.835
-
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature. 2021 08; 596(7871):268-272.
Score: 0.237
-
Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques. Nature. 2021 08; 596(7872):423-427.
Score: 0.060
-
Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. JAMA. 2021 06 15; 325(23):2370-2380.
Score: 0.059
-
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA. 2021 04 20; 325(15):1535-1544.
Score: 0.059
-
Publisher Correction: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2021 Feb; 590(7844):E25.
Score: 0.058
-
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020 10; 586(7830):583-588.
Score: 0.056
-
DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020 08 14; 369(6505):806-811.
Score: 0.055
-
SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020 08 14; 369(6505):812-817.
Score: 0.055
-
Publisher Correction: Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature. 2018 12; 564(7734):E8.
Score: 0.050
-
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. J Infect Dis. 2018 07 13; 218(4):633-644.
Score: 0.049
-
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018 07 21; 392(10143):232-243.
Score: 0.048
-
Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. J Virol. 2018 07 01; 92(13).
Score: 0.048